TEM
Tempus AI, Inc.
Price Chart
Latest Quote
$50.84
+2.05 (+4.20%)
Current Price
| Previous Close | $48.79 |
| Open | $50.00 |
| Day High | $51.01 |
| Day Low | $48.86 |
| Volume | 5,887,531 |
Stock Information
| Shares Outstanding | 174.52M |
| Total Debt | $1.32B |
| Cash Equivalents | $639.07M |
| Revenue | $1.36B |
| Net Income | $-302.91M |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | $9.13B |
| EPS (TTM) | $-1.72 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.76B |
| Sales | $1.36B |
| Income | $-302.91M |
| Book/sh | $2.32 |
| Cash/sh | $3.66 |
| Employees | 4K |
Financial Ratios
| Quick Ratio | 2.99 |
| Current Ratio | 3.31 |
| Debt/Eq | 316.65 |
Returns & Margins
| ROA | -9.07% |
| ROE | -81.58% |
| Gross Margin | 63.39% |
| Operating Margin | -24.33% |
| Profit Margin | -22.20% |
Ownership
| Insider Ownership | 37.12% |
| Institutional Ownership | 57.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -476.61 |
| P/S | 6.69 |
| P/B | 21.89 |
Analyst Data
| Recommendation | none |
| Target Price | $66.53 |
Technical Indicators
| SMA20 | $49.18 |
| SMA50 | $49.93 |
| SMA200 | $64.26 |
| RSI | 50.56 |
| ATR | 4.2028 |
| Shares Float | 114.07M |
| Short Float | 31.44% |
| Short Ratio | 4.72 |
| Volatility | 3.62 |
| Rel Volume | 0.81 |
Performance History
| Week | +2.52% |
| Month | +11.66% |
| Quarter | +4.31% |
| 6 Months | -25.36% |
| YTD | -18.47% |
| Year | -27.49% |
| 10 Years | +26.31% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $50.84 | 5,887,531 |
| 2026-06-17 | $48.79 | 6,055,900 |
| 2026-06-16 | $50.56 | 7,000,500 |
| 2026-06-15 | $52.32 | 10,237,400 |
| 2026-06-12 | $47.82 | 6,109,600 |
| 2026-06-11 | $49.59 | 6,587,900 |
| 2026-06-10 | $49.48 | 7,225,800 |
| 2026-06-09 | $48.82 | 7,351,300 |
| 2026-06-08 | $48.59 | 4,829,400 |
| 2026-06-05 | $46.43 | 8,873,500 |
| 2026-06-04 | $52.26 | 13,897,300 |
| 2026-06-03 | $47.51 | 6,471,100 |
| 2026-06-02 | $49.62 | 6,391,000 |
| 2026-06-01 | $52.80 | 9,746,200 |
| 2026-05-29 | $50.47 | 11,808,100 |
| 2026-05-28 | $51.29 | 10,381,000 |
| 2026-05-27 | $47.17 | 3,838,000 |
| 2026-05-26 | $46.66 | 4,395,800 |
| 2026-05-22 | $46.18 | 4,302,500 |
| 2026-05-21 | $46.49 | 3,833,800 |
| 2026-05-20 | $45.88 | 4,379,400 |
| 2026-05-19 | $45.53 | 5,851,100 |
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
đ° Latest News
Tempus Al, Inc. (TEM) Opens Open-Source Digital Pathology Consortium
Insider Monkey âĸ 2026-06-16T12:52:12Z
Tempus AI (TEM) Stock After 23% Year-To-Date Decline Is Opportunity Emerging
Simply Wall St. âĸ 2026-06-13T02:10:28Z
Tempus AI (TEM) Is One Of The Best Healthcare Mid-Cap AI Stock According To Analysts
Insider Monkey âĸ 2026-06-10T09:24:02Z
Assessing Tempus AI (TEM) Valuation After Recent Share Price Rebound And Underpriced Growth Narrative
Simply Wall St. âĸ 2026-06-05T15:15:07Z
Tempus (TEM) Gets Double-Digit Boost from New Partnerships
Insider Monkey âĸ 2026-06-05T01:17:23Z
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:28Z
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth
Insider Monkey âĸ 2026-06-02T09:38:04Z
Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades
Simply Wall St. âĸ 2026-06-01T06:12:42Z
Short Report: Tempus AI short interest at record high
TipRanks âĸ 2026-06-01T05:05:57Z
How The Tempus AI (TEM) Investment Story Is Shifting As Analysts Rework Their Models
Simply Wall St. âĸ 2026-05-30T05:02:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $387,875,000 | $287,258,000 | $220,633,000 | $190,482,000 |
| Cost Of Revenue | $473,892,000 | $312,285,000 | $245,647,000 | $190,482,000 |
| Total Revenue | $1,271,789,000 | $693,398,000 | $531,822,000 | $320,668,000 |
| Operating Revenue | $1,271,789,000 | $693,398,000 | $531,822,000 | $320,668,000 |
| Expenses | ||||
| Interest Expense | $70,267,000 | $53,653,000 | $46,869,000 | $21,894,000 |
| Total Expenses | $1,524,661,000 | $1,384,480,000 | $727,905,000 | $586,110,000 |
| Other Income Expense | $19,413,000 | $32,336,000 | $21,822,000 | $-4,846,000 |
| Other Non Operating Income Expenses | $31,447,000 | $32,336,000 | $21,822,000 | $-4,846,000 |
| Net Non Operating Interest Income Expense | $-57,639,000 | $-42,569,000 | $-39,268,000 | $-18,862,000 |
| Interest Expense Non Operating | $70,267,000 | $53,653,000 | $46,869,000 | $21,894,000 |
| Operating Expense | $1,050,769,000 | $1,072,195,000 | $482,258,000 | $395,628,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Net Interest Income | $-57,639,000 | $-42,569,000 | $-39,268,000 | $-18,862,000 |
| Interest Income | $12,628,000 | $11,084,000 | $7,601,000 | $3,032,000 |
| Normalized Income | $-235,131,238 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Net Income From Continuing And Discontinued Operation | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Total Operating Income As Reported | $-252,872,000 | $-691,082,000 | $-196,083,000 | $-265,442,000 |
| Net Income Common Stockholders | $-245,028,000 | $-746,330,000 | $-265,964,000 | $-333,928,000 |
| Net Income | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Net Income Including Noncontrolling Interests | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Net Income Continuous Operations | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Earnings From Equity Interest Net Of Tax | $-5,614,000 | $-4,228,000 | $-301,000 | $-595,000 |
| Pretax Income | $-291,098,000 | $-701,315,000 | $-213,529,000 | $-289,150,000 |
| Special Income Charges | $-12,034,000 | $0 | $0 | - |
| Interest Income Non Operating | $12,628,000 | $11,084,000 | $7,601,000 | $3,032,000 |
| Operating Income | $-252,872,000 | $-691,082,000 | $-196,083,000 | $-265,442,000 |
| Depreciation Amortization Depletion Income Statement | $16,307,000 | $12,218,000 | $8,318,000 | - |
| Depreciation And Amortization In Income Statement | $16,307,000 | $12,218,000 | $8,318,000 | - |
| Depreciation Income Statement | $16,307,000 | $12,218,000 | $8,318,000 | - |
| Gross Profit | $797,897,000 | $381,113,000 | $286,175,000 | $130,186,000 |
| Per Share | ||||
| Diluted EPS | $-1.41 | $-6.23 | $-1.61 | $-5.26 |
| Basic EPS | $-1.41 | $-6.23 | $-1.61 | $-5.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,137,238 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-106,473,000 | $-610,417,000 | $-133,328,000 | $-236,846,000 |
| Total Unusual Items | $-12,034,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-12,034,000 | $0 | $0 | - |
| Reconciled Depreciation | $102,324,000 | $37,245,000 | $33,332,000 | $30,410,000 |
| EBITDA (Bullshit earnings) | $-118,507,000 | $-610,417,000 | $-133,328,000 | $-236,846,000 |
| EBIT | $-220,831,000 | $-647,662,000 | $-166,660,000 | $-267,256,000 |
| Diluted Average Shares | $174,264,000 | $119,849,000 | $164,832,610 | $63,430,000 |
| Basic Average Shares | $174,264,000 | $119,849,000 | $164,832,610 | $63,430,000 |
| Diluted NI Availto Com Stockholders | $-245,028,000 | $-746,330,000 | $-265,964,000 | $-333,928,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $4,338,000 | $301,000 |
| Tax Provision | $-51,684,000 | $266,000 | $288,000 | $66,000 |
| Other Special Charges | $12,034,000 | - | - | - |
| Research And Development | $319,031,000 | $316,844,000 | $185,498,000 | $162,251,000 |
| Selling General And Administration | $715,431,000 | $743,133,000 | $288,442,000 | $233,377,000 |
| Preferred Stock Dividends | - | $40,521,000 | $47,508,000 | $43,816,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-334,138,000 | $-28,720,000 | $-1,477,433,000 | $-1,219,405,000 |
| Total Assets | $2,274,838,000 | $926,116,000 | $564,052,000 | $631,364,000 |
| Total Non Current Assets | $1,107,663,000 | $258,513,000 | $213,721,000 | $192,735,000 |
| Other Non Current Assets | $25,775,000 | $9,186,000 | $9,811,000 | $9,623,000 |
| Non Current Accounts Receivable | $16,215,000 | - | - | - |
| Goodwill And Other Intangible Assets | $825,464,000 | $85,059,000 | $95,270,000 | $90,378,000 |
| Other Intangible Assets | $355,253,000 | $11,716,000 | $21,916,000 | $37,278,000 |
| Current Assets | $1,167,175,000 | $667,603,000 | $350,331,000 | $438,629,000 |
| Other Current Assets | $40,498,000 | $26,135,000 | $17,295,000 | $19,450,000 |
| Inventory | $51,724,000 | $38,386,000 | $28,845,000 | $22,282,000 |
| Receivables | $319,955,000 | $154,819,000 | $94,462,000 | $88,684,000 |
| Accounts Receivable | $311,170,000 | $154,819,000 | $94,462,000 | $88,684,000 |
| Allowance For Doubtful Accounts Receivable | $-2,755,000 | $-1,141,000 | $-1,115,000 | $-2,942,000 |
| Gross Accounts Receivable | $313,925,000 | $155,960,000 | $95,577,000 | $91,626,000 |
| Cash Cash Equivalents And Short Term Investments | $754,998,000 | $448,263,000 | $197,574,000 | $302,938,000 |
| Cash And Cash Equivalents | $604,787,000 | $340,954,000 | $165,767,000 | $302,938,000 |
| Financial Assets | - | $0 | $26,429,000 | $24,948,000 |
| Hedging Assets Current | - | $0 | $5,070,000 | $0 |
| Current Deferred Assets | - | $0 | $7,085,000 | $5,275,000 |
| Debt | ||||
| Net Debt | $634,716,000 | $94,482,000 | $283,898,000 | $86,608,000 |
| Total Debt | $1,327,130,000 | $468,094,000 | $488,142,000 | $433,029,000 |
| Long Term Debt And Capital Lease Obligation | $1,313,775,000 | $461,635,000 | $481,705,000 | $426,671,000 |
| Long Term Debt | $1,239,503,000 | $435,436,000 | $449,665,000 | $389,546,000 |
| Current Debt And Capital Lease Obligation | $13,355,000 | $6,459,000 | $6,437,000 | $6,358,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,783,512,000 | $869,777,000 | $1,946,215,000 | $1,760,391,000 |
| Total Non Current Liabilities Net Minority Interest | $1,411,124,000 | $578,707,000 | $1,713,588,000 | $1,586,152,000 |
| Other Non Current Liabilities | $56,600,000 | $15,980,000 | $19,751,000 | $9,604,000 |
| Tradeand Other Payables Non Current | $12,393,000 | $70,450,000 | $55,321,000 | $39,485,000 |
| Non Current Deferred Liabilities | $28,356,000 | $30,642,000 | $16,768,000 | $35,136,000 |
| Current Liabilities | $372,388,000 | $291,070,000 | $232,627,000 | $174,239,000 |
| Other Current Liabilities | $8,680,000 | $6,964,000 | $8,213,000 | $2,355,000 |
| Current Deferred Liabilities | $108,628,000 | $91,936,000 | $64,860,000 | $50,142,000 |
| Payables And Accrued Expenses | $203,945,000 | $160,944,000 | $131,167,000 | $93,010,000 |
| Interest Payable | $2,828,000 | $8,660,000 | $8,863,000 | $459,000 |
| Payables | $82,333,000 | $78,243,000 | $64,218,000 | $51,612,000 |
| Total Tax Payable | $339,000 | $24,439,000 | $0 | - |
| Accounts Payable | $81,994,000 | $53,804,000 | $54,421,000 | $45,987,000 |
| Derivative Product Liabilities | - | $0 | $34,500,000 | $42,500,000 |
| Dividends Payable | - | $0 | $9,797,000 | $5,625,000 |
| Equity | ||||
| Common Stock Equity | $491,326,000 | $56,339,000 | $-1,382,163,000 | $-1,129,027,000 |
| Total Equity Gross Minority Interest | $491,326,000 | $56,339,000 | $-1,382,163,000 | $-1,129,027,000 |
| Stockholders Equity | $491,326,000 | $56,339,000 | $-1,382,163,000 | $-1,129,027,000 |
| Gains Losses Not Affecting Retained Earnings | $902,000 | $94,000 | $5,000 | $18,000 |
| Other Equity Adjustments | $902,000 | $94,000 | $5,000 | $18,000 |
| Retained Earnings | $-2,395,862,000 | $-2,150,834,000 | $-1,396,917,000 | $-1,138,302,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $1,105,543,000 | $1,026,143,000 |
| Long Term Equity Investment | $86,557,000 | $91,450,000 | $0 | - |
| Other | ||||
| Treasury Shares Number | $183,229 | $145,466 | - | - |
| Ordinary Shares Number | $178,279,217 | $161,975,295 | $164,832,610 | $164,832,610 |
| Share Issued | $178,462,446 | $162,120,761 | $164,832,610 | $164,832,610 |
| Tangible Book Value | $-334,138,000 | $-28,720,000 | $-1,477,433,000 | $-1,219,405,000 |
| Invested Capital | $1,730,829,000 | $491,775,000 | $-932,498,000 | $-739,481,000 |
| Working Capital | $794,787,000 | $376,533,000 | $117,704,000 | $264,390,000 |
| Capital Lease Obligations | $87,627,000 | $32,658,000 | $38,477,000 | $43,483,000 |
| Total Capitalization | $1,730,829,000 | $491,775,000 | $-932,498,000 | $-739,481,000 |
| Treasury Stock | $6,642,000 | $3,602,000 | $3,602,000 | $0 |
| Additional Paid In Capital | $2,892,910,000 | $2,210,664,000 | $18,345,000 | $9,251,000 |
| Capital Stock | $18,000 | $17,000 | $6,000 | $6,000 |
| Common Stock | $18,000 | $17,000 | $6,000 | $6,000 |
| Non Current Deferred Revenue | $28,356,000 | $30,642,000 | $16,768,000 | $35,136,000 |
| Long Term Capital Lease Obligation | $74,272,000 | $26,199,000 | $32,040,000 | $37,125,000 |
| Current Deferred Revenue | $108,628,000 | $91,936,000 | $64,860,000 | $50,142,000 |
| Current Capital Lease Obligation | $13,355,000 | $6,459,000 | $6,437,000 | $6,358,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,780,000 | $24,767,000 | $21,950,000 | $22,374,000 |
| Current Accrued Expenses | $121,612,000 | $82,701,000 | $66,949,000 | $41,398,000 |
| Duefrom Related Parties Non Current | $16,215,000 | $0 | - | - |
| Investments And Advances | $86,557,000 | $91,450,000 | $0 | - |
| Investmentsin Joint Venturesat Cost | $86,557,000 | $91,450,000 | $0 | - |
| Goodwill | $470,211,000 | $73,343,000 | $73,354,000 | $53,100,000 |
| Net PPE | $153,652,000 | $72,818,000 | $82,211,000 | $67,786,000 |
| Accumulated Depreciation | $-137,346,000 | $-105,397,000 | $-79,041,000 | $-58,245,000 |
| Gross PPE | $290,998,000 | $178,215,000 | $161,252,000 | $126,031,000 |
| Leases | $64,791,000 | $46,809,000 | $42,433,000 | $30,390,000 |
| Other Properties | $208,147,000 | $124,773,000 | $112,186,000 | $89,008,000 |
| Machinery Furniture Equipment | $6,976,000 | $6,633,000 | $6,633,000 | $6,633,000 |
| Buildings And Improvements | $1,234,000 | $0 | - | - |
| Land And Improvements | $9,850,000 | $0 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $8,785,000 | $0 | - | - |
| Other Short Term Investments | $150,211,000 | $107,309,000 | $31,807,000 | $0 |
| Non Current Accrued Expenses | - | - | $0 | $6,613,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-245,355,000 | $-211,166,000 | $-248,947,000 | $-186,581,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-218,090,000 | $-189,045,000 | $-214,339,000 | $-168,204,000 |
| Cash Flow From Continuing Operating Activities | $-218,090,000 | $-189,045,000 | $-214,339,000 | $-168,204,000 |
| Operating Gains Losses | $1,592,000 | $-39,358,000 | $-21,606,000 | $5,295,000 |
| Investing Activities | ||||
| Capital Expenditure | $-27,265,000 | $-22,121,000 | $-34,608,000 | $-18,377,000 |
| Investing Cash Flow | $-398,355,000 | $-130,392,000 | $-40,313,000 | $-57,939,000 |
| Cash Flow From Continuing Investing Activities | $-398,355,000 | $-130,392,000 | $-40,313,000 | $-57,939,000 |
| Capital Expenditure Reported | $-6,216,000 | $0 | $0 | - |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-3,040,000 | $-2,250,000 | $-3,602,000 | $0 |
| Issuance Of Capital Stock | $195,499,000 | $581,701,000 | $44,885,000 | $92,199,000 |
| Financing Cash Flow | $884,123,000 | $494,329,000 | $117,547,000 | $251,391,000 |
| Cash Flow From Continuing Financing Activities | $884,123,000 | $494,329,000 | $117,547,000 | $251,391,000 |
| Net Other Financing Charges | $-44,100,000 | $-79,497,000 | $-698,000 | $-5,433,000 |
| Cash Dividends Paid | $0 | $-5,625,000 | $-5,625,000 | $-5,625,000 |
| Net Preferred Stock Issuance | $0 | $197,500,000 | $44,885,000 | $92,199,000 |
| Preferred Stock Issuance | $0 | $199,750,000 | $44,885,000 | $92,199,000 |
| Net Common Stock Issuance | $192,459,000 | $381,951,000 | $-3,602,000 | $0 |
| Common Stock Issuance | $195,499,000 | $381,951,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-284,733,000 | $0 | $-288,000 | $-375,000 |
| Issuance Of Debt | $1,020,497,000 | $0 | $82,875,000 | $170,625,000 |
| End Cash Position | $609,451,000 | $341,835,000 | $166,607,000 | $303,731,000 |
| Beginning Cash Position | $341,835,000 | $166,607,000 | $303,731,000 | $278,466,000 |
| Effect Of Exchange Rate Changes | $-62,000 | $336,000 | $-19,000 | $17,000 |
| Changes In Cash | $267,678,000 | $174,892,000 | $-137,105,000 | $25,248,000 |
| Preferred Stock Payments | $0 | $-2,250,000 | $0 | $0 |
| Common Stock Payments | $-3,040,000 | $0 | $-3,602,000 | $0 |
| Net Issuance Payments Of Debt | $735,764,000 | $0 | $82,587,000 | $170,250,000 |
| Net Long Term Debt Issuance | $735,764,000 | $0 | $82,587,000 | $170,250,000 |
| Long Term Debt Payments | $-284,733,000 | $0 | $-288,000 | $-375,000 |
| Long Term Debt Issuance | $1,020,497,000 | $0 | $82,875,000 | $170,625,000 |
| Net Investment Purchase And Sale | $5,576,000 | $-13,085,000 | $0 | $0 |
| Sale Of Investment | $8,316,000 | $23,098,000 | $0 | $0 |
| Purchase Of Investment | $-2,740,000 | $-36,183,000 | $0 | $0 |
| Net Business Purchase And Sale | $-376,666,000 | $-95,186,000 | $-5,705,000 | $-39,562,000 |
| Purchase Of Business | $-376,666,000 | $-95,186,000 | $-5,705,000 | $-39,562,000 |
| Net PPE Purchase And Sale | $-21,049,000 | $-22,121,000 | $-34,608,000 | $-18,377,000 |
| Purchase Of PPE | $-21,049,000 | $-22,121,000 | $-34,608,000 | $-18,377,000 |
| Change In Working Capital | $-178,547,000 | $-37,803,000 | $-37,837,000 | $71,819,000 |
| Change In Other Working Capital | $-22,915,000 | $18,945,000 | $-26,412,000 | $67,626,000 |
| Change In Other Current Liabilities | $-14,948,000 | $-8,553,000 | $-8,761,000 | $-7,439,000 |
| Change In Other Current Assets | $-42,301,000 | $-751,000 | $-4,209,000 | $-2,296,000 |
| Change In Payables And Accrued Expense | $-2,913,000 | $36,817,000 | $21,929,000 | $24,537,000 |
| Change In Accrued Expense | $4,328,000 | $60,669,000 | $45,292,000 | $32,452,000 |
| Change In Interest Payable | $14,206,000 | $15,129,000 | $15,836,000 | $16,395,000 |
| Change In Payable | $-7,241,000 | $-23,852,000 | $-23,363,000 | $-7,915,000 |
| Change In Account Payable | $-7,241,000 | $-23,852,000 | $-23,363,000 | $-7,915,000 |
| Change In Prepaid Assets | $-1,699,000 | $-13,683,000 | $-6,474,000 | $-1,094,000 |
| Change In Inventory | $-3,369,000 | $-9,541,000 | $-6,563,000 | $-1,312,000 |
| Change In Receivables | $-90,402,000 | $-61,037,000 | $-7,347,000 | $-8,203,000 |
| Changes In Account Receivables | $-90,402,000 | $-61,037,000 | $-7,347,000 | $-8,203,000 |
| Other Non Cash Items | $25,594,000 | $21,862,000 | $16,885,000 | $8,278,000 |
| Stock Based Compensation | $124,747,000 | $534,138,000 | $0 | $0 |
| Provisionand Write Offof Assets | $3,893,000 | $680,000 | $1,646,000 | $5,805,000 |
| Asset Impairment Charge | $0 | $0 | $7,359,000 | $0 |
| Deferred Tax | $-52,665,000 | $0 | $0 | - |
| Deferred Income Tax | $-52,665,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $102,324,000 | $37,245,000 | $33,332,000 | $30,410,000 |
| Depreciation And Amortization | $102,324,000 | $37,245,000 | $33,332,000 | $30,410,000 |
| Depreciation | $102,324,000 | $37,245,000 | $33,332,000 | $30,410,000 |
| Earnings Losses From Equity Investments | $5,614,000 | $4,228,000 | $301,000 | $595,000 |
| Gain Loss On Investment Securities | $-16,471,000 | $-43,586,000 | $-21,907,000 | $4,700,000 |
| Gain Loss On Sale Of PPE | $415,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-245,028,000 | $-705,809,000 | $-214,118,000 | $-289,811,000 |
| Interest Paid Supplemental Data | - | $28,045,000 | $16,913,000 | $4,664,000 |
| Income Tax Paid Supplemental Data | - | $206,000 | $161,000 | $6,000 |
Fetched: 2026-06-15